BioMedReports: There has been some talk about the upcoming opening of your new state-of-the-art facility. Can you tell us about that?
CEO Matthew L. Schissler: We always try to focus on three core goals and in 2010 we are opening our new state of the art laboratory. One of those three core goals is the diversification of revenue streams. Not only will we have our own organic growth engine, by processing and storing for our own company, but we recently entered into a letter of agreement to process and store for another very successful stem cell company. That’s
Aastrom Biosciences, Inc. (Nasdaq:ASTMD), a leading developer of autologous cellular therapies for the treatment of severe cardiovascular diseases, today reported results from a planned interim analysis of the company’s multi-center, randomized, double-blind, placebo-controlled U.S. Phase 2b clinical trial designated RESTORE-CLI. According to the interim analysis the safety profile was similar between the treatment and placebo arms.
Based on a composite efficacy endpoint assessing time to treatment failure (including major amputations, wound size and gangrene), Aastrom’s autologous vascular repair cells (VRCs) were more effective than placebo (P<0.05). Other clinically meaningful endpoints (e.g., major amputation rate, complete wound closure) approached but did
A blood sample databank under the China Marrow Donor Program (CMDP), was officially established Monday at Zhongguancun of Beijing.
The new databank is now the largest for Chinese people in the world, according to Hong Junling, deputy head of CMDP management center.
The databank includes information such as the names and gender of nearly one million donors and information about to which ethnic groups the donors come from, Hong said.
It also covers such medical information as blood types, gene types and health status of the donors.
The CMDP, launched in 2001 by the Red Cross Society of China, aims to help millions
Stem Cell Research Study Reveals Stroke Patients Helped by Own Stem Cells
A new stem cell research study/trial recently completed shows that implanting a person’s own Adult Stem Cells helps stroke patients overcome partial paralysis. Dr. Kameshwar Prasad of the All India Institute of Medical Sciences (AIIMS) will present his stem cell study […]
Image via Wikipedia
Scientists have made a breakthrough in stem cell research which raises the prospect of regrowing damaged sections of a person’s liver, pancreas or even their brain.
Researchers at the University of NSW have found a way to improve the lifespan and competitiveness of stem cells, overcoming a problem which otherwise saw their regenerative powers fade in about an hour.
Adult stem cells were given a gene to make them resistant to chemotherapy, handing them an “advantage” when used to treat damaged tissue in conjunction with the cancer-fighting treatment.
University of NSW Professor Peter Gunning said as the chemotherapy cleaned out